B+
Bull case
25%
Probability
Target price
$4.80
+20.0% vs current
RZLT
RezoluteFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$3.50
-12.5% vs current
B-
Bear case
30%
Probability
Target price
$2.10
-47.5% vs current
AI sentiment snapshot
Latest data as of 2026-04-18
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+33.6
Score
AI commentary
Neutral-to-cautious. The deterministic prior is neutral with only middling evidence quality, and the primary-source record supports that stance: sunRIZE missed pivotal endpoints, yet the March 24, 2026 FDA update kept a path alive via further agency review rather than ending the program outright [#8-K-2026-03-24]. The 10-Q also shows a solid near-term cash cushion, but not enough to remove medium-term financing risk if H2 2026 does not deliver a clearer clinical or regulatory win [#10-Q-2026-02-12].
RankAlpha Sentiment Codex - 2026-04-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30eventFDA review of sunRIZE data package and program path decisionHigh impact
After sunRIZE missed its primary and key secondary endpoints, FDA encouraged Rezolute to submit comprehensive study reports and analysis datasets, with the company expecting a program update in the second half of 2026; this is the clearest near-term value inflection for congenital HI and remains binary despite a more constructive tone than an outright setback [#8-K-2026-03-24].
2026-11-15eventPhase 3 upLIFT topline data in tumor hyperinsulinismHigh impact
Rezolute said the Phase 3 upLIFT study for tumor HI is ongoing and that topline results are expected in the second half of 2026; with congenital HI now less certain, investor focus may shift heavily toward whether upLIFT can supply a cleaner efficacy signal for ersodetug in another HI setting [#PR-2025-12-11].
2026-12-31catalystCash runway is adequate near term but financing overhang likely re-emerges before commercialization clarityHigh impact
The December 31, 2025 10-Q showed $132.9 million of cash plus short-term marketable debt securities, which management said should fund obligations, ongoing trials, and planned activities for at least 12 months from the filing date; however, the same filing also says the company expects to continue raising capital over the next several years, leaving dilution risk as a persistent medium-term overhang if regulatory or clinical timelines slip [#10-Q-2026-02-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-18 • Updated nightlySource: Internal modelMethodology